Alzheimer in Biological Technology

EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator

...racterization of the development candidate EVP-0962. EVP-0962 is a proprietary small molecule that belongs to a new generation of potential alzheimer drugs known as gamma-secretase modulators (GSMs). As a gamma-secretase modulator, EVP-0962 selectively inhibits the production of the toxic AB42 pept...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

...IENNA, Austria, July 14 /PRNewswire-FirstCall/ -- Elan Corporation, plc (NYSE: ELN ) and Wyeth (NYSE: WYE ) presented information this week at the alzheimer Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) from seven posters and one podium presentation about the growing burden o...

ROCK STARS OF SCIENCE: Prana's Co-Founding Scientist, Rudy Tanzi Teams up with Star-Powered Cast in GQ Photoshoot

...k about how much faster we will be able to raise the funds needed to cure diseases like Alzheimer's," commented Dr. Tanzi. One of three prominent alzheimer researchers featured, Dr. Tanzi has been instrumental in the quest for developing a cure to the disease. He has identified and characterized several...

Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.

...to form oligomers and to aggregate. Dr Glabe, an author of the paper, noted, "These results are very exciting news for understanding the mechanism of alzheimer pathogenesis. They help elucidate the fundamental role of metal ions like zinc in causing the formation of Abeta oligomers which damage synapses". ...

Progress toward an Alzheimer's drug that saves brain cells

...ir research on Alzheimer's disease, the researchers have used mouse models. They have found that deactivating the variant, Aph1B γ-secretase, in alzheimer mice leads to reduced formation of the plaques, without any harmful side effects. Importance of the research With this discovery, the researche...

Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference

... About ICAD The Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) is the largest gathering of international leaders in alzheimer research and care. At ICAD, researchers from around the world share groundbreaking information and resources on the cause, diagnosis, treatment and pr...

Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award

...e visit www.eisai.com . About the Alzheimer's Association The Alzheimer's Association is the leading voluntary health organization in alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and suppo...

ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia

...y under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and le...

JCI table of contents: April 22, 2008

...OGY: One protein, opposite effects on a characteristic of some neurodegenerative disorders One of the characteristics of the brain of people with alzheimer disease (AD) is the presence of tangles, insoluble twisted fibers that build up inside the nerve cells of the brain resulting in malfunctions in commu...

Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease

...he treatment of mild to moderate stage Alzheimer's disease. The oral presentation, "Intravenous Immunoglobulin Increases Brain Glucose Metabolism in alzheimer Disease," will also be presented on April 17 and will discuss the analysis of brain activity using imaging data. The brain metabolism results were bas...

Clinical Update - Debio 9902 SR in Alzheimer's Disease

...incipal Investigator in the United Kingdom, who presented this recommendation at the 10th International Hong Kong Springfield Symposium on Advances in alzheimer Therapy. About Debio 9902 SR Debio 9902 SR is a novel AChE inhibitor which is administered once every 4 weeks. It is transformed non-enzymatically...

Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease

...s in Alzheimer's disease. AB, which is known to accumulate in the brains of alzheimer patients, has long been a focus of research into the causes and treatment o...imer-related cognitive impairments." Physicians have long recognized that alzheimer patients have a higher incidence of convulsive seizures than reference popu...